Sydney Children's Hospital

Running trials

• Recruiting

  A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

  NCT07221669· Phase 3· Biogen· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

  NCT07287982· Phase 2· argenx· Source

• Recruiting

  Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  NCT06333899· Early phase 1· Nationwide Children's Hospital· Source

• Recruiting

  HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis

  NCT06175104· Children's Hospital Medical Center, Cincinnati· Source

• Recruiting

  ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  NCT06838676· Phase 2· Nationwide Children's Hospital· Source

• Active, not recruiting

  A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

  NCT06953583· Phase 3· Biogen· Source

• Enrolling by invitation

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

  NCT06908226· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  Study of Olutasidenib and Temozolomide in HGG

  NCT06161974· Phase 2· Rigel Pharmaceuticals· Source

• Recruiting

  A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

  NCT07334301· Phase 1/2· University of Birmingham· Source

• Active, not recruiting

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

  NCT06719141· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

  NCT06660394· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  NCT05843253· Phase 2· Nationwide Children's Hospital· Source

• Recruiting

  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· AbbVie· Source

• Recruiting

  Targeted Pediatric High-Grade Glioma Therapy

  NCT05839379· Nationwide Children's Hospital· Source

• Recruiting

  Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

  NCT06208657· Phase 1/2· Australian & New Zealand Children's Haematology/Oncology Group· Source

• Recruiting

  A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

  NCT06392386· Phase 2/3· argenx· Source

• Recruiting

  CTNNB1 Neurodevelopmental Syndrome - Natural History Study

  NCT07167732· University Medical Centre Ljubljana· Source

• Recruiting

  A Study of Pitolisant in Patients With Prader-Willi Syndrome

  NCT06366464· Phase 3· Harmony Biosciences Management, Inc.· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

  NCT05286788· Phase 2· Nationwide Children's Hospital· Source

• Active, not recruiting

  Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC)

  NCT05667766· Murdoch Childrens Research Institute· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

  NCT05233397· Phase 2· Nationwide Children's Hospital· Source

• Recruiting

  Precision Medicine for Every Child With Cancer

  NCT05504772· Australian & New Zealand Children's Haematology/Oncology Group· Source

• Active, not recruiting

  Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

  NCT05286801· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  NCT05476770· Phase 1· Therapeutic Advances in Childhood Leukemia Consortium· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  NCT05304585· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  Combination Therapy for the Treatment of Diffuse Midline Gliomas

  NCT05009992· Phase 2· University of California, San Francisco· Source

• Active, not recruiting

  A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  NCT04994132· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

  NCT04774718· Phase 1/2· Hoffmann-La Roche· Source

• Recruiting

  A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

  NCT04684368· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

  NCT04775485· Phase 2· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  NCT04655404· Early phase 1· Nationwide Children's Hospital· Source

• Recruiting

  Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

  NCT06651580· M.D. Anderson Cancer Center· Source

• Recruiting

  Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer

  NCT04903782· Sydney Children's Hospitals Network· Source

• Active, not recruiting

  Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

  NCT04323046· Phase 1· Sabine Mueller, MD, PhD· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· University of Birmingham· Source

• Recruiting

  A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  NCT04293562· Phase 3· Children's Oncology Group· Source

• Recruiting

  INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

  NCT03838042· Phase 1/2· University Hospital Heidelberg· Source

• Active, not recruiting

  Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

  NCT04042025· Phase 3· Novartis Gene Therapies· Source

• Active, not recruiting

  A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

  NCT03779334· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349· Phase 2· Children's Oncology Group· Source

Showing 50 of 65.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers26 recruiting
• Glioblastoma4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Neuroblastoma3 recruiting
• Sarcoma3 recruiting
• Spinal muscular atrophy2 recruiting
• Type 1 diabetes2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Autism1 recruiting
• Congenital heart disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Epilepsy1 recruiting
• Hodgkin lymphoma1 recruiting
• Kidney cancer1 recruiting
• Myasthenia gravis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Completed

  A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

  NCT05115110· Phase 2/3· Hoffmann-La Roche· Source

• Completed

  Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

  NCT04966741· Phase 3· Rhythm Pharmaceuticals, Inc.· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Takeda· Source

• Completed

  A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

  NCT04773782· Phase 1/2· Blueprint Medicines Corporation· Source

• Completed

  Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

  NCT05067634· Phase 3· SK Life Science, Inc.· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Takeda· Source

• Completed

  Tricaprilin Infantile Spasms Pilot Study

  NCT04727970· Phase 1· Cerecin· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Terminated

  An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

  NCT04912856· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

  NCT04447755· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

  NCT04897880· Phase 2· Australian & New Zealand Children's Haematology/Oncology Group· Source

• Completed

  Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

  NCT03790332· Phase 1/2· Pharmacyclics LLC.· Source

• Completed

  COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

  NCT03206021· Phase 1· The Hospital for Sick Children· Source

• Completed

  Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

  NCT02879643· Phase 1· Therapeutic Advances in Childhood Leukemia Consortium· Source

• Completed

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666· Phase 2· Children's Oncology Group· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Children's Oncology Group· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Children's Oncology Group· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

  NCT00336024· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Children's Oncology Group· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Children's Oncology Group· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Children's Oncology Group· Source

• Completed

  Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

  NCT00085202· Phase 3· St. Jude Children's Research Hospital· Source

• Completed

  Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

  NCT00026312· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241· Children's Oncology Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Childhood cancers35 works · 70 trials
• Cystic fibrosis17 works · 1 trial
• Spinal muscular atrophy12 works · 5 trials